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UROGENITAL ATROPHY 
David Sturdee on behalf of the British Menopause Society Council (Updated from the 
previous guidelines by Joan Pitkin and Margaret Rees in 2008) 
Summary 
The British Menopause Society Council aims to aid health professionals in providing up to 
date and informed advice about post reproductive health. This guidance refers to the long 
term, but often ignored condition of urogenital atrophy resulting from postmenopausal 
estrogen deficiency. Treatment should be based on up to date information and targeted to 
the needs of the individual woman. Non-estrogen and estrogen containing treatments are 
discussed. 
Introduction 
Unlike hot flushes which resolve spontaneously in time, atrophic symptoms affecting the 
vagina and lower urinary tract are often progressive, lasting for many years and frequently 
require treatment. The prevalence of vaginal dryness increases as a woman advances 
through the postmenopausal years, causing itching, burning, and dyspareunia, and sexual 
activity is often compromised. While up to 40% of women will experience symptoms at 
some time, only a minority (about 25% in the Western world) will seek medical help. Some 
of this is due to lack of education about what women might expect after the menopause but 
also to the adverse publicity for hormone replacement therapy(HRT) and the mistaken 
belief that local treatment of vaginal atrophy is similar to HRT. Other reasons for the 
continued suffering in silence may be cultural and an understandable reluctance to discuss 
such matters, but the medical profession must also take much of the blame for failing to 
enquire of all postmenopausal women about the possibility of vaginal atrophic symptoms 
[1]. 
Pathophysiology 
Estrogen receptors are present in the vagina, urethra and bladder trigone and with the 
decline in circulating estradiol after the menopause, there is inevitably some degree of 
atrophic change in these areas. In particular the vaginal epithelium becomes thin and loses 
its rugae and elasticity and is visibly paler due to the reduced blood supply, though when  
symptomatic the introitus may appear acutely inflamed and tender. There is reduced 
glycogen in the superficial cells causing an increased pH due to lower production of lactic 
acid, which reduces resistance to the growth of pathogens. Cervical secretions and vaginal 
transudation are also decreased leading to reduced lubrication. Atrophic urethritis and 
trigonitis can cause dysuria, frequency, urgency, bladder pain and recurrent urinary 
infections. Atrophy of the vulval skin and labia may contribute to pruritus. 
Treatment 
Symptomatic urogenital atrophy is easy to diagnose, but too often it is missed or not 
presented. Simple questioning of all postmenopausal women, regardless of the initial 
reason for consulting, will elicit the classic symptoms. The principles of treatment of 
established vaginal atrophy are the restoration of urogenital physiology and the alleviation 
of symptoms. Treatment should be started early and before irrevocable changes have 
occurred [1]. 
Non-hormonal lubricants and moisturisers 
Lubricants and moisturisers are available without prescription, though can be expensive; 
some can be prescribed (Replens, Sylk, Hyalofemme and Regelle). These are mainly a 
combination of protectants and thickening agents in a water-soluble base, and are primarily 
of use to relieve vaginal dryness during intercourse, but do not provide a long-term solution 
or restore urogenital physiology [2,3]. Moisturisers can help to retain water in the 
superficial cells of the vagina and thus have some longer effects. 
The integrity and efficacy of condoms may be compromised by lubricants such as petroleum 
based products and baby oil. This can be important when condoms are used to prevent 
sexually transmitted infections [4]. 
Estrogen 
Estrogen may be given either systemically or locally, but 10-25% of women using systemic 
hormone therapy alone will still experience the symptoms of urogenital atrophy. This 
finding plus the safety concerns about oral/transdermal HRT are the reasons why systemic 
therapy is not usually recommended for women with vaginal symptoms only [5], though, in 
women with severe symptoms, a combination of systemic and vaginal estrogen may be 
necessary initially [1]. Local therapy options include low dose natural estrogens such as 
estradiol by tablet or ring, or estriol by cream or pessary. Conjugated equine estrogen cream 
is no longer used as it tends to be absorbed more readily in to the circulation and has 
caused endometrial stimulation and bleeding [6]. Systemic absorption occurs with all topical 
estrogen preparations but is low with estradiol vaginal tablets or ring and hormone levels 
remain within the normal postmenopausal range [7,8].Absorption is greatest during the first 
few days, when the vaginal epithelium is still atrophic. Once it has matured, absorption 
decreases and smaller doses of estrogen will prevent recurring atrophy, which needs to be 
continued indefinitely. Considerable absorption of estriol is seen from both creams and 
pessaries but, since estriol is a weak estrogen, which is not converted to estrone or 
estradiol, systemic effects are limited [9]. There is no evidence of endometrial stimulation 
when estradiol or estriol preparations are used appropriately and thus there is no need for 
additional progestogen for endometrial protection [1,6,10,11]. However, if unexpected 
postmenopausal bleeding does occur this should be investigated. 
All estrogen preparations have a beneficial effect on urogenital atrophy, relieving vaginal 
dryness, dyspareunia and reducing urinary infections. Tablets and rings cause less discharge 
compared to pessaries and creams. Individual patient preference will determine the choice 
of product[6].There are no studies of the use of local estrogen beyond 12 months, but long-
term use of low-dose estrogen is not contra-indicated [1]. It is regrettable that 60% of 
British postmenopausal women are unaware of the availability and effects of local estrogen 
and fewer receive prescriptions than women in Scandinavia and North America [12]. 
In the presence of urogenital atrophy, the changes in the cervix can cause cervical smears to 
be unsatisfactory for assessment. The squamo-columnar junction may recede into the 
cervical canal making colposcopic examination unsatisfactory also. The use of local estrogen 
for a few weeks can resolve these problems. 
Vaginal atrophy is a common result of the treatment of many gynaecological and breast 
cancers but, there are insufficient data on the use of local estrogen in women with 
hormone-responsive cancers to provide an evidence-based guidance. Use of local estrogen 
therapy in women on tamoxifen or aromatase inhibitors needs careful counselling and 
discussion with the oncology team [1]. 
Future  
Ospemifene, an orally active selective estrogen receptor modulator (SERM) has been 
licensed in N America for the treatment of urogenital atrophy and may become available in 
the UK soon [13]. 
Practice points 
 Symptoms due to urogenital atrophy are common but are under-recognised and 
under-treated by healthcare professionals 
 Treatment should be started early and before irrevocable changes have occurred 
 Treatment needs to be continued to maintain the benefits 
 All local estrogen preparations are effective and patient preference will usually 
determine the treatment used 
 Additional progestogen is not indicated when appropriate low-dose local estrogen is 
used 
 If estrogen is ineffective or undesired, vaginal moisturizers and lubricants can give 
temporary relief from symptoms due to vaginal dryness 
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